LH Stock Overview
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Laboratory Corporation of America Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$199.97 |
| 52 Week High | US$243.30 |
| 52 Week Low | US$195.01 |
| Beta | 0.99 |
| 1 Month Change | -4.57% |
| 3 Month Change | -12.03% |
| 1 Year Change | -13.54% |
| 3 Year Change | -23.49% |
| 5 Year Change | 29.88% |
| Change since IPO | 720.39% |
Recent News & Updates
Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Apr 15
Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark
Apr 06Recent updates
Laboratory Corporation of America Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Apr 15Laboratory Corporation of America Holdings' (NYSE:LH) P/E Is On The Mark
Apr 06Laboratory Corporation: A Healthier Diagnosis, As Pandemic Headwinds Disappear
Apr 01Laboratory Corporation of America Holdings (NYSE:LH) Will Pay A Dividend Of $0.72
Feb 25We Think You Can Look Beyond Laboratory Corporation of America Holdings' (NYSE:LH) Lackluster Earnings
Feb 22An Intrinsic Calculation For Laboratory Corporation of America Holdings (NYSE:LH) Suggests It's 48% Undervalued
Feb 21Laboratory Corporation of America Holdings (NYSE:LH) Has Affirmed Its Dividend Of $0.72
Jan 31Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly
Jan 30Laboratory Corporation of America Holdings' (NYSE:LH) Dividend Will Be $0.72
Jan 15Some Shareholders Feeling Restless Over Laboratory Corporation of America Holdings' (NYSE:LH) P/E Ratio
Jan 05Laboratory Corporation: Multiple Updates, Same Investment Conclusion
Dec 02Laboratory Corp.: Rate On Capital Deployed Contracting, Hold
Sep 14Laboratory Corporation: Trying To Create Value By Spinning Out Fortrea
Jul 05Newsflash: Laboratory Corporation of America Holdings (NYSE:LH) Analysts Have Been Trimming Their Revenue Forecasts
Jul 04Are Investors Undervaluing Laboratory Corporation of America Holdings (NYSE:LH) By 43%?
Jun 23Laboratory Corporation: Predictability Of Cash Flows Less Visible
Jun 21Is It Too Late To Consider Buying Laboratory Corporation of America Holdings (NYSE:LH)?
May 26Laboratory Corporation of America Holdings' (NYSE:LH) Returns On Capital Are Heading Higher
Mar 16Laboratory Corporation of America Holdings (NYSE:LH) Shares Could Be 32% Below Their Intrinsic Value Estimate
Mar 02Laboratory Corporation of America Non-GAAP EPS of $4.14 in-line, revenue of $3.7B misses by $40M, introduces FY23 outlook
Feb 16At US$254, Is It Time To Put Laboratory Corporation of America Holdings (NYSE:LH) On Your Watch List?
Jan 30Laboratory Corporation: Plenty Of Growth Runway
Jan 19Here's Why Laboratory Corporation of America Holdings (NYSE:LH) Can Manage Its Debt Responsibly
Jan 16Laboratory Corporation of America declares $0.72 dividend
Jan 12Returns At Laboratory Corporation of America Holdings (NYSE:LH) Are On The Way Up
Dec 07Is There An Opportunity With Laboratory Corporation of America Holdings' (NYSE:LH) 25% Undervaluation?
Nov 24Laboratory Corporation: Buy Rating Holds Following Solid Mid-Level Growth
Nov 08Laboratory Corporation of America Q3 2022 Earnings Preview
Oct 26We Think Laboratory Corporation of America Holdings (NYSE:LH) Can Stay On Top Of Its Debt
Oct 14Laboratory Corporation of America declares $0.72 dividend
Oct 12Is Laboratory Corporation of America Holdings (NYSE:LH) Potentially Undervalued?
Sep 28LabCorp to pay $273M to company for infringing prenatal test patents - Bloomberg
Sep 23LabCorp: Drug Development Segment Spinoff Poised To Generate Significant Value
Aug 23Shareholder Returns
| LH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -3.5% | 2.4% | -3.7% |
| 1Y | -13.5% | 0.8% | 20.5% |
Return vs Industry: LH underperformed the US Healthcare industry which returned -2.9% over the past year.
Return vs Market: LH underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| LH volatility | |
|---|---|
| LH Average Weekly Movement | 2.5% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LH has not had significant price volatility in the past 3 months.
Volatility Over Time: LH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 61,975 | Adam Schechter | www.labcorp.com |
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Laboratory Corporation of America Holdings Fundamentals Summary
| LH fundamental statistics | |
|---|---|
| Market cap | US$16.99b |
| Earnings (TTM) | US$379.20m |
| Revenue (TTM) | US$12.16b |
44.4x
P/E Ratio1.4x
P/S RatioIs LH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LH income statement (TTM) | |
|---|---|
| Revenue | US$12.16b |
| Cost of Revenue | US$8.80b |
| Gross Profit | US$3.36b |
| Other Expenses | US$2.99b |
| Earnings | US$379.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 4.51 |
| Gross Margin | 27.67% |
| Net Profit Margin | 3.12% |
| Debt/Equity Ratio | 64.1% |
How did LH perform over the long term?
See historical performance and comparisonDividends
1.4%
Current Dividend Yield66%
Payout RatioDoes LH pay a reliable dividends?
See LH dividend history and benchmarks| Laboratory Corporation of America Holdings dividend dates | |
|---|---|
| Ex Dividend Date | May 28 2024 |
| Dividend Pay Date | Jun 12 2024 |
| Days until Ex dividend | 40 days |
| Days until Dividend pay date | 55 days |
Does LH pay a reliable dividends?
See LH dividend history and benchmarks